Botulinum Toxin Type A (AGN-151607) for the Prevention of Post-operative Atrial Fibrillation in Adult Participants Undergoing Open-chest Cardiac Surgery (NOVA)
Completed · Phase 2 · NCT03779841
Conditions: Post-Operative Atrial Fibrillation
At a glance
- Research payments reported, 2025
- $67
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 323
About the trial
- Sponsor
- AbbVie
- Tested
- AGN-151607 (drug), Placebo (drug)
- Dates
- Started 2019-03-01; completion 2023-03-06
- Results posted
- Yes
This was a multi-center, randomized, double-blind, placebo-controlled, parallel group, dose-ranging study to evaluate the efficacy and safety of botulinum toxin type A (AGN-151607) injections into the epicardial fat pads, foci of ganglionic plexi, to prevent Post-Operative Atrial Fibrillation (POAF) in patients undergoing open-chest cardiac surgery.
From ClinicalTrials.gov, last updated 2024-05-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $67 in research payments for this study in 2025 (1 payments).
Products named: Botox
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $67
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.